Login to Your Account

'Nucleic Acid Powerhouse' Built By Cureon, Pantheco Merger

By Cormac Sheridan

Wednesday, March 12, 2003
Cureon A/S and Pantheco A/S, two Danish firms that specialize in developing antisense drugs based on DNA analogue chemistry, disclosed plans to merge in a stock-based transaction that would create a "nucleic acid powerhouse" focusing initially on cancer therapy. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription